Health and Human Services (HHS)/Assistant Secretary for Preparedness and Response (ASPR)/Biomedical Advanced Research and Development Authority (BARDA), Thomas P. O'Neill Federal Building (FOB8), 200 C Street, SW, Washington, DC 20024, United States.
Health and Human Services (HHS)/Assistant Secretary for Preparedness and Response (ASPR)/Biomedical Advanced Research and Development Authority (BARDA), Thomas P. O'Neill Federal Building (FOB8), 200 C Street, SW, Washington, DC 20024, United States.
Vaccine. 2019 Nov 15;37(48):7178-7182. doi: 10.1016/j.vaccine.2017.10.111. Epub 2017 Dec 2.
The Ebola virus epidemic in West Africa proved to be the largest in the history of filovirus outbreaks, causing the World Health Organization to declare a public health emergency of international concern in August of 2014. In collaboration with domestic and international partners, the Biomedical Advanced Research and Development Authority (BARDA) initiated several vaccine development projects in support of the overall response efforts. The urgency associated with the epidemic triggered the clinical evaluation of lead vaccine candidates starting in late 2014. Here we will discuss development of the lead vaccine candidates for Ebola virus, specifically Zaire ebolavirus.
西非的埃博拉病毒疫情被证明是有史以来最大的丝状病毒疫情爆发，世界卫生组织于 2014 年 8 月宣布这是国际关注的突发公共卫生事件。生物医学高级研究与发展管理局（BARDA）与国内外合作伙伴合作，启动了多个疫苗开发项目，以支持整体应对工作。疫情的紧迫性促使人们在 2014 年底开始对主要候选疫苗进行临床评估。在这里，我们将讨论针对埃博拉病毒（特别是扎伊尔埃博拉病毒）的主要候选疫苗的开发。
